AACR17 audience

AACR17 audience in Washington DC

Over the last few years we’ve written a tremendous about primary and acquired resistance, both in oncogenic and immunotherapies, as well as on combination strategies for turning non-responders into responders and overcoming acquired resistance that induces clinical relapse.

These concepts were still on display in Washington DC at the 2017 annual meeting for American Association for Cancer Research (AACR), but beyond those obvious top line points, what are the next round of ideas and tools that cancer researchers are focusing on?

Based on numerous presentations, ad hoc discussions, as well as over a dozen one to one interviews we completed with oncology thought leaders, some useful and encouraging trends emerged.

To learn more insights, subscribers can log in

Posted by